SBIR/STTR Research Award
Fibronectin matrix mimetic, Chimectin as a first-in-class therapeutic for chronic wound healing
Award amount
$388,193Program and phase
SBIR · Phase IAward year
2024Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- EDI THERAPEUTICS LLC
- Proposal award date
- 2024-05-01
- Contract end date
- 2025-04-30
- UEI
- P6VEXK48QFJ8
- Solicitation number
- PA23-230
- Topic code
- 200
Research abstract
ABSTRACT Chronic wounds have become a `silent epidemic' with health complications ranging from serious infections to limb amputations to death. In the U.S. alone, annual health care costs for treating chronic wounds are conservatively estimated at $32 billion. Treatment approaches for chronic wounds include surgical debridement, moist dressings, engineered skin substitutes, compression therapy, negative pressure therapy, skin grafts, and recombinant growth factors. Yet, none of these approaches has proven to be an efficient and effective therapy. Tissue repair occurs through a series of events mediated through interactions between various cell types and extracellular matrix (ECM) proteins. Fibronectin fibrils are a principal component of the wound ECM and play a key role in tissue formation. The Hocking lab has developed a series of soluble, recombinant fragments of fibronectin, termed “fibronectin matrix mimetics”, that “mimic” the structural and functional properties of insoluble fibronectin fibrils. Fibronectin matrix mimetics promote cell adhesion, proliferation, migration and contractility, modulate extracellular matrix composition, and induce local vasodilation - all of which contribute to effective tissue regeneration. Topical application of fibronectin matrix mimetics to full-thickness dermal wounds in diabetic mice accelerates epithelial maturation, and promotes granulation tissue deposition, remodeling, and re-vascularization. Thus, a primary target of the fibronectin matrix mimetics is chronic diabetic wounds. The goals of this project are to (i) fully characterize tissue responses to one of the fibronectin matrix mimetics, FNIII1H,8,10 (“Chimectin”) in genetically diabetic male and female mice, and (ii) test Chimectin's efficacy in a diabetic porcine dermal wound model. Results from these studies will lay the groundwork to advance Chimectin to clinical trials to test its ability to stimulate wound healing in diabetic patients.
Technology keywords
Not reported
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- Electromagnetic reprogramming of systemic metabolism for the treatment of type 2 diabetes
- Next-Gen Oral Therapeutics for Type 2 Diabetes
- Oral Therapeutics Platform for Treating Inborn Errors of Amino Acid Metabolism
- Development of novel therapeutics for obesity and type 2 diabetes
- Metrifonate local application for DFU treatment